Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2022-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司2022年半年度报告_摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive details. The document length is 2277 characters, which is relatively short but contains substantive financial data and analysis for the half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains actual financial statements and substantive financial data. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2022
2022-08-25 Chinese
哈药集团股份有限公司独立董事关于公司九届二十九次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of 哈药集团股份有限公司 regarding specific board meeting matters, specifically about changes in accounting policies and asset impairment provisions. It references compliance with laws and accounting standards but does not contain full financial statements or comprehensive financial data. The document is a formal opinion related to board decisions rather than a full audit report or annual report. It is not a certification letter or a brief announcement. Given the content focuses on board-related opinions on accounting matters, it fits best under Board/Management Information (MANG). The document length is short and focused on board opinions, not a full report or announcement of a report publication.
2022-08-25 Chinese
哈药集团股份有限公司关于公司副总经理辞职的公告
Board/Management Information Classification · 100% confidence The document is a short announcement regarding the resignation of the company's vice general manager. It includes a statement from the board ensuring the accuracy of the announcement. There is no financial data, no mention of reports, no voting results, or other regulatory filings. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2022-08-09 Chinese
哈药集团股份有限公司2022年半年度业绩预减公告
Earnings Release Classification · 95% confidence The document is titled as a "2022 年半年度业绩预减公告" which translates to "2022 Half-Year Performance Profit Warning Announcement." It provides an earnings forecast for the half-year period ending June 30, 2022, including expected net profit and reasons for the decrease compared to the prior year. The document explicitly states that the forecast is preliminary and unaudited, and it is an announcement of expected financial results rather than a full interim or quarterly report containing actual financial statements or detailed analysis. The document length is short (1307 characters), and it serves as a profit warning or earnings guidance announcement rather than a comprehensive financial report. Therefore, it fits best under the Earnings Release (ER) category, which covers initial announcements of quarterly or periodical financial results with key highlights only. H1 2022
2022-07-14 Chinese
北京安杰（上海）律师事务所关于哈药集团股份有限公司2021年股票期权与限制性股票激励计划回购注销部分限制性股票相关事宜之法律意见书
Regulatory Filings
2022-07-14 Chinese
哈药集团股份有限公司关于2021年股票期权与限制性股票激励计划中部分限制性股票回购注销实施公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the repurchase and cancellation of restricted shares under a stock option and restricted stock incentive plan. It details the number of shares repurchased and cancelled, the reasons for the repurchase (employee departures), the board approvals, and legal opinions. It does not contain financial statements or detailed financial performance data. The document is a formal disclosure of a share repurchase and cancellation event related to stock incentives, which fits the category of Transaction in Own Shares (POS). The document length is 2463 characters, which is relatively short and focused on a specific corporate action rather than a full report or financial results. Therefore, the appropriate classification is POS with high confidence.
2022-07-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.